Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Bladder Cancer treatment details. Biologic therapy. Memorial Sloan-Kettering Cancer Center, New York, NY, United States



Survival: 7.1 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
   
Drugs:
Country: United States
   
City/State/Province: New York, NY
   
Hospital: Memorial Sloan-Kettering Cancer Center
   
Journal: Link
   
Date: 2/2010

Description:
Patients:
This phase II trial involved 45 previously-treated metastatic urothelial cancer patients with a median age of 64 years; 71% were male.

Treatment:
Patients were treated with the biologic therapy agent sunitinib, which is an inhibitor of proteins involved in supporting tumor blood supply.

Toxicities:
There was one reported treatment-related death due to heart attack. Grade 4 nausea, fatigue, lymphopenia, and thrombocytopenia were also reported.

Results:
The median overall survival was 7.1 months.

Support:
This study was partially supported by Pfizer Inc., the makers of sunitinib (Brand name: Sutent).

Correspondence: Dr. Dean Bajorin; email: bajorind@mskcc.org

E-mail to a Friend Email Physician More Information